C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Republic of Korea)
Inventor
Lee, Yuhan
Karp, Jeffrey M.
Park, Seongiun
Nam, Kum Seok
Park, Geonhu
Kim, Yeji
Hwang, Kiwook
Abstract
A pressure-sensitive adhesive (PSA), method of manufacturing a PSA, and various uses thereof synergistically combines the advantages of viscoelastic PSAs and bioadhesives. Enabled by a one-pot scalable copolymerization of a polyester and hydrophilic polymer, the PSA provides near-instant (~ 1 s), robust, and repeatable (over 1,000 times) adhesion to wet biological tissues (i.e., skin, lung, heart) and engineering (i.e., metals, plastics) substrates without prior surface functionalization.
A61F 13/0246 - Adhesive bandages or dressings characterised by the skin-adhering layer
C09J 167/03 - Polyesters derived from dicarboxylic acids and dihydroxy compounds the dicarboxylic acids and dihydroxy compounds having the hydroxy and the carboxyl groups directly linked to aromatic rings
C09J 7/25 - PlasticsMetallised plastics based on macromolecular compounds obtained otherwise than by reactions involving only carbon-to-carbon unsaturated bonds
3.
METHODS FOR GENERATING FUNCTIONAL HEMATOPOIETIC STEM CELLS
Described in the present application are methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, using mechanical stretching or Trpv4 agonists, and methods of use of the HSCs in transplantation. In some embodiments, the methods include providing a population comprising hemogenic endothelial (HE) cells, and (i) contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4); and/or (ii) subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Also provided herein are methods for treating subjects who have, bone marrow, metabolic, and immune diseases; the methods include administering to the subject a therapeutically effective amount of hematopoietic stem cells (HSCs) obtained by a method described herein.
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
This disclosure relates to pectin-based polymer compositions and methods of use thereof to cover, protect, and seal injuries, e.g., surgical wounds, in a mesothelial tissue. The methods include obtaining a bioadhesive pectin-based polymer composition including a complex of high-methoxyl pectin (HMP) and carboxymethylcellulose (CMC) in a ratio from about 10 to 1 to 1 to 10 by weight; applying the composition to an injured mesothelial tissue; and applying pressure for at least one minute to enable the composition to bind to the mesothelial tissue.
The present disclosure relates to methods of identifying and treating kidney rejection in a subject comprising analyzing RNA, including microvesicular RNA.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
7.
COMPOSITIONS AND METHODS FOR CHARACTERIZING HEPATOCYTE STRESS
The disclosure provides compositions and methods for identifying subjects having hepatocyte stress associated with a risk for developing hepatocellular carcinoma (HCC), and therapeutic methods for reducing a subject's risk of HCC, for example, by inhibiting RELB, SOX4, or HMGCS2.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
8.
SYSTEMS AND METHODS FOR EVALUATION OF CIRCADIAN RHYTHM AND SLEEP HOMEOSTASIS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
Inventor
Mignot, Emmanuel
Specht, Adrien
Duffy, Jeanne F.
Abstract
Systems and methods for assessment of circadian rhythm and sleep homeostasis are described. Presence of proteinaceous biomarkers within an individual's biological sample can be utilized in a computational classifier to indicate rhythmic phase and/or sleep homeostasis. Further clinical analysis and/or treatments can be performed based on determined rhythmic phase or sleep homeostasis.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
9.
MOUNTING DEVICE OF A STEREOTACTIC SYSTEM AND METHOD OF USE THEREOF
A stereotactic system for attachment to a skull of a patient can include a mounting device that can include a mounting base configured to be attached to the skull, a sheath removably attached to the mounting base, a guide frame, and a guide member. The guide frame has a frame body that removably attaches to the mounting base and receives the sheath, a plurality of arms extending outwardly from the frame body, and a plurality of fiducials attached to the plurality of arms. The guide member is received within the frame body and receives the sheath such that the sheath is pivotable relative to the mounting base within the guide member. The guide member is configured to fixedly secure the sheath to the mounting base.
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61B 1/317 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes for bones or joints, e.g. osteoscopes, arthroscopes
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/10 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis
10.
SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Provided herein are methods and compositions for determining if a subject diagnosed with a CEACAM1-related disease or disorder is administered a CEACAM1 antibody or antigen-binding agent as a treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
12.
TREATMENT OF SOLID TUMORS WITH IMPLANTABLE POLYMERS WITH SMALL MOLECULES OR CELLS
Disclosed are implantable polymers that release therapeutic agents in proximity to a tumor in a patient. In some embodiments, a polyethylene glycol hydrogel can release a STING agonist and/or a CAR-T cell in proximity to a phosphatase and tensin homolog (PTEN)-null triple negative breast cancer (TNBC) in the patient.
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 9/52 - Sustained or differential release type
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Disclosed are implantable polymers that release therapeutic agents in proximity to a tumor in a patient. In some embodiments, a polyethylene glycol hydrogel can release a small molecule, like a STING agonist in proximity to a phosphatase and tensin homolog (PTEN)-null triple negative breast cancer (TNBC) in the patient.
THE BRIGHAM AND WOMEN'S HOSPITAL INCORPORATED (USA)
Inventor
Masaki, Fumitaro
Ninni, Brian
King, Franklin
Hata, Nobuhiko
Abstract
A system for, display controller connected to, and a method of, operating a robotic catheter system which is configured to manipulate a catheter having one or more bending segments along the catheter's length and a catheter tip at the distal end thereof, and which includes an actuator unit coupled to the bending segments via one or more drive wires arranged along a wall of the catheter. The method comprising: inserting at least part of the catheter into a lumen along an insertion trajectory that spans from an insertion point to a target; causing the actuator unit to actuate at least one of the one or more drive wires to align the catheter tip with the target; determining the position and/or orientation of the catheter tip with respect to the target; and displaying information about an accuracy of alignment between the catheter tip with respect to the target.
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
15.
DETERMINING WHETHER AN IBD PATIENT WILL RESPOND TO 5-ASA THERAPY
The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
16.
METHODS OF PREDICTING RELAPSE POST HEMATOPOIETIC STEM-CELL TRANSPLANTATION AND METHODS OF TREATMENT
Methods of predicting relapse in a patient post HSCT, and methods of treatment, the methods including obtaining a bone marrow sample from the patient post- transplantation; and determining TCR clonal diversity of a population of T cells within the bone marrow sample; wherein TCR clonal diversity is indicative of risk of relapse.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Described herein are termination-readthrough-based gene switches that are small (only 9 nucleotides) and do not introduce any foreign protein into the target cell, and that can be used to alter expression levels of transgenes in a cell.
A therapeutic or diagnostic delivery system, and methods of making and using the same, are disclosed. The system is a solvent free, injectable, biodegradable, and in situ crosslinking depot (ISCD) platform for ultra-long-term release of hydrophilic drugs.
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure related to methods of treating various diseases that can benefit from modulating angiogenesis and/or endothelial-to-mesenchymal transition (EndMT) pathways, such as retinopathies and cancer, by modulating family with sequence similarity 222 member A (FAM222A) expression in the endothelium (e.g., endothelial cells) of a subject. For example, FAM222A can be modulated with FAM222A inhibitors described herein, thereby reducing angiogenesis, or FAM222A activators described herein, thereby increasing angiogenesis.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
System, methods, and non-transitory computer readable medium (CRM) are provided that are directed to a biological age model utilizing metabolomic and proteomic data. Additional clinical variables and DNA methylation data may also be delivered to the methods, systems, and CRM. The biological age model determines a morbidity parameter based on a comparison between a patient's determined biological age and their chronological age to determine a time until death and possible treatment strategies.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G01N 33/483 - Physical analysis of biological material
22.
SYSTEMS AND METHODS FOR STIMULATION, NERVE REPAIR AND/OR DRUG DELIVERY
Systems and methods for nerve repair can include a polymer configured to form an elongated conduit to receive an in vivo nerve therein and provide a mechanical stabilization to the in vivo nerve. The polymer can be configured to degrade upon being subjected to a dissolution solution to remove the mechanical stabilization from the in vivo nerve.
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 17/00 - Surgical instruments, devices or methods
A sono-ink composition is described that includes a acrylate oligomer, an acoustic absorber, and a thermal initiator. A method of using the sono-ink for deep-penetrating volumetric printing is also described. The method includes the steps of a) providing a volume of a sono-ink composition, comprising a acrylate oligomer, an acoustic absorber, and a thermal initiator; b) directing a focused acoustic projection of ultrasound waves into the volume of the sono-ink, wherein the focused acoustic projection of ultrasound waves has an intensity and frequency sufficient to activate the thermal initiator so that local polymerization is achieved at a desired region within the volume of sono-ink; and c) optionally repeating step b wherein the focused acoustic projection of ultrasound waves is directed to selected regions within the sono-ink, until a three-dimensional object is formed.
B29C 35/02 - Heating or curing, e.g. crosslinking or vulcanising
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
B29C 64/165 - Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
B33Y 80/00 - Products made by additive manufacturing
C08F 2/56 - Polymerisation initiated by wave energy or particle radiation by ultrasonic vibrations
C08F 265/06 - Polymerisation of acrylate or methacrylate esters on to polymers thereof
C08H 1/00 - Macromolecular products derived from proteins
B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
24.
INGESTIBLE AND/OR IMPLANTABLE ARTICLES FOR MONITORING ELECTRICAL SIGNALS AND RELATED METHODS
Some aspects of the present disclosure are related to articles for measuring electrical signals internal to a subject, e.g., of the gastrointestinal tract (GI tract). The articles, in some embodiments, are ingestible and/or implantable. In some embodiments, the articles comprise a substrate comprising a plurality of electrodes, the substrate having a Young's elastic modulus of greater than or equal to 0.01 MPa and less than or equal to 200 MPa. In some such cases, the Young's elastic modulus of the substrate facilitates elastic recoil of the substrate such that at least a portion of the plurality of electrodes contact a surface of a tissue at the location internal to the subject (e.g., the GI tract) and thus facilitate measurement of electrical signals at the location internal to the subject. Other aspects are related to methods of using the articles, for example, to monitor electrical signals from the location internal to the subject.
The disclosure provides improved methods and devices to create a hammock effect to stabilize the urethra without creating an incision in the abdomen or the vagina, and without using a surgical mesh. Such implementations can also leave no permanent material in the body. The simplicity afforded by such procedures and methods permits treatment of patients on an outpatient basis, and avoids risks and disadvantages associated with the installation of a permanent mesh.
A61B 17/42 - Gynaecological or obstetrical instruments or methods
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
Genome wide association studies (GWAS) have demonstrated the power of genetics to detect previously unrecognized contributions to disease biology. To date one limitation has been the modest effect sizes of many of the detected loci, and the lack of a predictable relationship between the locus and specific mechanisms. These features have prevented the large-scale identification of new genetic targets for therapeutic intervention for all but a small number of GWAS loci. To directly address these limitations and build on the success of GWAS, the present disclosure presents a series of specific biological tools and analytics, which when combined with relevant clinical data at scale, enable the systematic discovery of previously unknown disease subsets, previously unknown disease genes of significant effect, previously unknown therapeutic targets, and disease-to-pharmacology matching at the individual patient level.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
27.
INGESTIBLE AND/OR IMPLANTABLE ARTICLES FOR MONITORING ELECTRICAL SIGNALS AND RELATED METHODS
Some aspects of the present disclosure are related to articles for measuring electrical signals internal to a subject, e.g., of the gastrointestinal tract (GI tract). The articles, in some embodiments, are ingestible and/or implantable. In some embodiments, the articles comprise a substrate comprising a plurality of electrodes, the substrate having a Young's elastic modulus of greater than or equal to 0.01 MPa and less than or equal to 200 MPa. In some such cases, the Young's elastic modulus of the substrate facilitates elastic recoil of the substrate such that at least a portion of the plurality of electrodes contact a surface of a tissue at the location internal to the subject (e.g., the GI tract) and thus facilitate measurement of electrical signals at the location internal to the subject. Other aspects are related to methods of using the articles, for example, to monitor electrical signals from the location internal to the subject.
C07K 5/03 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link in which at least a delta-amino acid is involved, e.g. isosteres
in situin situin situ after injection into the tissue of the subject, wherein molecules of the drug are released via surface erosion from the implant. The implant may include a packing efficiency above 97%, and the drug may comprise microcrystals. The composition may be injectable by hand using a needle with a gauge of in a range of 16-30G, wherein the injection by hand includes less than 64 N of force at a 6 mL/minute injection rate.
An intra-abdominal injection system includes a fluid reservoir, a needle, a plunger, and a dissolvable capsule. The plunger is movable between a first position and a second position. When the plunger moves between the first and second position, a fluid from the fluid reservoir flows through the needle. The dissolvable capsule encases each of the fluid reservoir, the plunger, and the needle such that, until the capsule is dissolved during ingestion of the intra-abdominal injection system, the plunger is restricted from being moved from the first position to the second position.
A device configured to be implanted in a subject includes a sensing module, a therapeutic module, and a battery. The sensing module includes at least two of an accelerometer, an electrocardiogram (ECG) sensor, a photoplethysmogram (PPG) sensor, and a temperature sensor. The therapeutic module includes a drug reservoir and a reciprocating pump. The battery powers the sensing module and the therapeutic module. The sensing module is configured to detect a biological event in the subject and, upon detection of the biological event, send a signal to the therapeutic module. The therapeutic module is configured to receive the signal from the sensing module and, upon receiving the signal, administer a drug to the subject from the drug reservoir via the pump.
Provided herein are methods of generating Gata6-positive brown adipose progenitor cells, and brown adipose cells and tissue therefrom. Additionally, provided herein are methods of generating UCP1 positive organoids. Generally, the methods include a step of culturing brown adipose progenitor cells in a medium containing an FGF signaling pathway activator, a BMP signaling pathway activator, a TGFβ activator, a Wnt inhibitor, and a thyroid hormone receptor activator.
A medical information processing apparatus according to an embodiment includes a first analysis unit, a second analysis unit, a determination unit, and a third analysis unit. The first analysis unit executes a first analysis based on a medical image of a subject. The second analysis unit executes a second analysis based on a specimen examination result of the subject. The determination unit determines a matching degree between the result of the first analysis by the first analysis unit and the result of the second analysis by the second analysis unit. The third analysis unit executes a third analysis based on the medical image and the specimen examination result according to analysis conditions based on the determination result of the matching degree by the determination unit, and determines diagnosis support information based on the medical image and the specimen examination result.
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Methods for risk assessment, diagnosis, monitoring during therapy, or monitoring for recurrence for patients with known or suspected ovarian cancer are provided. These methods employ a statistical model and combine detection of microRNA biomarkers and protein biomarkers.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
A medical information processing apparatus according to an embodiment includes processing circuitry configured to acquire a medical image obtained by imaging a subject, acquire a value of a biomarker contained in a sample collected from the subject, determine a region of interest on the acquired medical image, analyze the image of the determined region of interest and calculate a property of a drawn object, select a value of a biomarker associated with the calculated property of the drawn object, and determine consistency between the selected value of the biomarker and the calculated property of the drawn object.
Aspects of the present disclosure relate to an article. In some embodiments, the article is a gastric retention device or a gastrointestinal device. In some embodiments, the article comprises one or more reservoirs comprising a therapeutic payload. In some embodiments, the article comprises one or more triggerable release mechanisms. In some embodiments, the triggerable release mechanism comprises a metal seal. In some embodiments, release of the therapeutic payload is accomplished via electrochemical dissolution of the metal seal. Other aspects of the disclosure relate to methods for delivering a drug using the drug delivery articles disclosed herein.
37.
NOVEL COMPOSITIONS, METHODS OF MANUFACTURE AND USES THEREOF
Provided herein are nanobody-conjugated nanoparticles and methods of use thereof, e.g., for targeted delivery or accumulation of the nanoparticles in selected tissues.
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 27/00 - Biocides, pest repellants or attractants, or plant growth regulators containing hydrocarbons
38.
PROGRAMMABLE LIPID NANOPARTICLE DELIVERY VIA CORONA PROTEIN ENGINEERING
Disclosed are compositions comprising a lipid nanoparticle and a modified biomolecular corona. In some embodiments, the modified biomolecular corona comprises a fused cell-specific binding domain. In some embodiments, the modified biomolecular corona protein has been additionally modified such that it does not bind substantially to its natural receptor. In some embodiments, the fused cell-specific binding domain binds to a target cell.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Aspects of the disclosure relate to compositions and methods for targeted protein degradation. In some embodiments, the disclosure relates to methods of evolving protein degrons to interact with certain small molecule inducers (e.g., VS-777, PT-179, or PK-1016). In some embodiments, the disclosure relates to compositions (e.g., peptides, nucleic acids encoding the protein degrons, etc.) used for targeted protein degradation. In some embodiments, the disclosure relates to methods of degrading a target polypeptide in a cell.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Described herein are fusion proteins for detecting analytes in test samples. Also described herein are methods for detecting analytes in test samples using such fusion protein. Further provided herein are systems or kits comprising such fusion proteins for detection of analytes in test samples.
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
Disclosed herein are methods of preparing and analyzing samples for biomarkers associated with placenta accreta in pregnant subjects. Also disclosed are method of assessing the risk of placenta accreta in pregnant subjects.
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
42.
SYSTEMS AND METHODS FOR PROMOTION OF ANGIOGENESIS AND ADIPOGENESIS IN TISSUES THROUGH APPLICATION OF MECHANICAL FORCES
A system and method for promoting angiogenesis and adipogenesis in soft tissue using a tissue enlargement apparatus. The tissue enlargement apparatus includes an interface configured for affixation to the soft tissue. A force generating device is coupled to the interface by a connecting tube for applying mechanical forces to the soft tissue. A processor is coupled to the force generating device and is configured to apply intermittent cyclical patterns of the mechanical forces to the soft tissue to promote angiogenesis and adipogenesis in soft tissue. The intermittent cyclical patterns are based on at least one of duration, frequency, and intensity of the mechanical forces.
Pseudomonas aeruginosaP. aeruginosa)P. aeruginosa), which poses significant health threats to humans. From this, Applicants isolated a compound that effectively activated complement immunity to inhibit bacterial growth. Furthermore, Applicants developed a robust testing platform for complement-recruiting compounds, allowing the streamlined assessment of ternary complex formatoon and the efficacy of novel bifunctional molecules for recruiting the complement system and inhibiting bacterial growth. These findings demonstrate the potential of this approach in combating antibiotic-resistant P. aeruginosa infections, with implications for other bacterial pathogens or diseases.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier, compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM).
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/00 - Drugs for disorders of the nervous system
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
45.
SYSTEM AND METHOD FOR PERCUTANEOUS DEPLOYMENT OF SENSORS
A method for tracking the location of a tissue mass comprising disposing a J-bar and electrical lead assembly within a needle cannula lumen; disposing the needle cannula within an outer cannula lumen; inserting the outer cannula into the anatomy of the patient; moving the needle cannula distally relative to the outer cannula; applying a force so that the J-bar and electrical lead assembly moves distally such that the fiducial sensor is anchored proximate to the tissue mass; moving the outer cannula and needle cannula proximally in concert, until the distal end of the outer cannula and the distal end of the needle cannula are disposed at the surface of the skin; applying a force so that the expandable basket moves distally, such that the expandable basket is disposed at the surface of the patient's skin with the electrical lead extending between the fiducial sensor and the expandable basket.
Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
47.
DIRECTED DEGRON MOLECULES AND APPLICATIONS THEREOF
This invention is related to molecules and methods of use of said molecules or compounds comprising said molecules. A molecule may be a pomalidomide or a thalidomide analogue. A method of inducing degradation of a target protein comprising one or more zinc finger polypeptides in a cell may comprise exposing a cell transfected with the target protein with a molecule as described herein, a pharmaceutically acceptable salt thereof, or any combination thereof. A method of inducing degradation of a target protein comprising one or more FK506 binding protein (FKBP) domains or degradation of a target amine in a cell may comprise exposing a cell transfected with the target protein or comprising the target amine with a composition comprising a molecule as described herein, a pharmaceutically acceptable salt thereof, or any combination of compositions comprising molecules as described herein and pharmaceutically acceptable salts thereof. A method may improve on-target effects and reduce off-target effects.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics.
The technology described herein relates to methods of inhibiting Peptidoglycan Recognition Protein 1 (Pglyrp1) in order to improve immune-checkpoint inhibitor treatments for cancer and autoimmune diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods for diagnosing, treating, and monitoring the treatment of histoplasmosis. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having histoplasmosis.
G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
C12Q 1/18 - Testing for antimicrobial activity of a material
Tissue explants of the gastrointestinal tract are provided. Methods of making and using the tissue explants are also provided, along with substrates designed for the tissue explants described.
The present disclosure reveals a process for the determination of a risk for the development of cardiovascular disease (CVD) in the future from quantitative analysis of four specific IgG N-glycans isolated from a blood sample of examined human subjects. Said four specific glycans were found to be significant diagnostic markers by statistical analysis of the results obtained from previously performed clinical trials that revealed the variation of quantitative IgG glycans content in the blood plasma in a cohort of normal subjects, versus, those who experienced CVD clinical manifestations. From this analysis, a new numerical model was developed which enables the calculation of the CVD risk parameter (CVDR). The numerical value for CVDR obtained after the inclusion of the result of said four key glycans, obtained from the blood analysis, gives an assessment of the eventual CVD development in the examined subject in the future.
The present disclosure relates to compositions having a lipid-like compound of Gm-Cn, as well as methods of making and using such compositions. Also described herein are methods of treating cancer using such compounds with a combination therapy.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Technology provided herein relates to methods of treating cancer comprising administering to a subject in need thereof a first stem cell (SC) modified to release an oncolytic virus and a second SC which is gene edited to inactivate a receptor for the oncolytic virus, thereby generating a stem cell resistant to the virus, wherein the second SC is also engineered to express an immunomodulatory polypeptide agent. Compositions comprising a first and second SC, and uses thereof, are also provided herein.
Insulin therapy revolutionized the care of patients with diabetes, yet insulin-induced hypoglycemia remains a serious life-threatening complication of insulin therapy. Glucagon is a highly effective treatment for hypoglycemia; however, current dosage forms remain under- utilized due to poor patient compliance. High-density, readily soluble, and thermostable solid glucagon formulations applied with painless, application-specific microneedle-patches can treat hypoglycemia in type 1 diabetes patients who are awake or asleep. On-demand patches can prevent or treat mild hypoglycemia during the day, and enzyme-driven hypoglycemia-responsive patches can release glucagon autonomously during the night. These patches have excellent in vitro glucagon stability, loading, and release kinetics and can treat hypoglycemia in diabetic humans and animals. These delivery systems enable new modes of glucagon therapy, thereby expanding the clinical role of glucagon beyond the emergency setting.
Ingestible and/or implantable low power battery and signaling systems are generally provided. Advantageously, the systems and methods described herein may provide, in some embodiments, secure communication such that only authorized users and/or medical professionals can read sensor data and/or send valid commands to a system. Advantageously, the system and methods described herein may provide, in some embodiments, an energy-efficient security protocol to further improve the wireless communication (e.g., of an ingestible and/or implantable article). In some embodiments, the security protocol advantageously provides data encryption to protect sensor and command information and mutual authentication to prevent unauthorized access to both ingestible and external devices.
The present disclosure relates, at least in part, to methods and cells useful for promoting ubiquitination-independent protein degradation and for promoting protein stability using an engineered midnolin protein.
Insulin therapy revolutionized the care of patients with diabetes, yet insulin-induced hypoglycemia remains a serious life-threatening complication of insulin therapy. Glucagon is a highly effective treatment for hypoglycemia; however, current dosage forms remain under-utilized due to poor patient compliance. High-density, readily soluble, and thermostable solid glucagon formulations applied with painless, application-specific microneedle-patches can treat hypoglycemia in type 1 diabetes patients who are awake or asleep. On-demand patches can prevent or treat mild hypoglycemia during the day, and enzyme-driven hypoglycemia-responsive patches can release glucagon autonomously during the night. These patches have excellent in vitro glucagon stability, loading, and release kinetics and can treat hypoglycemia in diabetic humans and animals. These delivery systems enable new modes of glucagon therapy, thereby expanding the clinical role of glucagon beyond the emergency setting.
The invention features a method of estimating an epigenetic age of a single cell from a mammalian tissue, the method comprising: creating a reference methylation probability data set comprising estimates in the change in average methylation levels with age for each CpG site in a plurality of CpG sites, creating a filtered methylation profile of the single cell comprising a defined number of CpG sites that exhibit the greatest absolute Pearson correlation with an age in the reference methylation probability data set, wherein the CpG sites are those common between the single cell and the reference methylation probability dataset, calculating the likelihood of observing the filtered methylation profile of the single cell for a plurality of ages, and determining the age for which the likelihood is greatest among the ages in the plurality of ages to produce the epigenetic age of the single cell. This method, when modified, is also amenable to estimate epigenetic age from shallow methylation sequencing data in bulk samples. Altogether, this framework enables both high-resolution epigenetic age profiling in single cells, combined with drastic cost-reduction for shallow bulk epigenetic age profiling.
Disclosed are systems and methods for adjusting an infusion rate of a drug being delivered to a patient. The method includes extracting a fluid sample from the patient, isolating a drug filtrate by processing the fluid sample within a first time period, and analyzing the drug filtrate for a drug concentration using chromatography system, a mass spectrometry system, or both within a second time period. The method further includes comparing, using a control process, the drug concentration with a target concentration range, and adjusting the infusion rate of the drug to ensure the drug concentration is within the target concentration range.
e.g.e.g.e.g., for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia. The present disclosure also provides piperidine-1-carboxylate compounds radiolabeled with a radioisotope, such as 11C, 18F, or 123/125I, and method of using the radiolabeled compounds for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) brain imaging agents for diagnosis and/or monitoring treatment of the neurodegenerative disorders.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 271/32 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
C07C 271/40 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
62.
PROTEOLYSIS TARGETING CHIMERAS FOR TREATING NEURODEGENERATION
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
e.g.e.g.e.g., for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia. The present disclosure also provides benzo[c][1,2,5]thiadiazolyl compounds radiolabeled with a radioisotope, such as 11C, 18F, or 123/125I, and method of using the radiolabeled compounds for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) brain imaging agents for diagnosis and/or monitoring treatment of the neurodegenerative disorders.
A method for generating electron density maps of a region of interest of a subject for adaptive radiation therapy using a magnetic resonance (MR) linear accelerator (Linac) radiation treatment system includes receiving a radiation treatment plan associated with the region of interest of the subject, acquiring a plurality of projections using one or more X-ray beams from a linear accelerator and a flat panel detector of the MR-Linac system, reconstructing one or more projection images based on the one or more projections, generating one or more electron density maps based on the one or more projection images, and generating an updated radiation treatment plan associated with the region of interest of the subject based on the one or more electron density maps.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
H05H 7/22 - Details of linear accelerators, e.g. drift tubes
Examples of such autonomous navigation, movement detection, and/or control include, but are not limited to, autonomous navigation of one or more portions of a continuum robot towards a particular target, movement detection of the continuum robot, Follow-The-Leader smoothing, and/or state change(s) for a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for gastro-intestinal, cardio, bronchial, and/or ophthalmic applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing and imaging efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
66.
AUTONOMOUS PLANNING AND NAVIGATION OF A CONTINUUM ROBOT WITH VOICE INPUT
Examples of such autonomous navigation, movement detection, and/or control include, but are not limited to, autonomous navigation of one or more portions of a continuum robot towards a particular target, movement detection of the continuum robot, Follow-The-Leader smoothing, and/or state change(s) for a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for Gastro-intestinal, cardio, bronchial, and/or ophthalmic applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing and imaging efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
67.
DEVICE MOVEMENT DETECTION AND NAVIGATION PLANNING AND/OR AUTONOMOUS NAVIGATION FOR A CONTINUUM ROBOT OR ENDOSCOPIC DEVICE OR SYSTEM
One or more devices, systems, methods, and storage mediums for performing navigation planning, autonomous navigation, movement detection, and/or control for a continuum robot are provided herein. Examples of such planning, autonomous navigation, movement detection, and/or control include, but are not limited to, navigation planning and/or autonomous navigation of one or more portions of a continuum robot towards a particular target, movement detection of the continuum robot, Follow-The-Leader smoothing, and/or state change(s) for a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for Gastro-intestinal, cardio, bronchial, and/or ophthalmic applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing and imaging efficiency while achieving images that are more precise, and also achieve reduced mental and physical burden and improved ease of use.
This technology describes novel cell based combined therapeutic modalities that include a stem cell engineered to secrete a multispecific T cell engager (MiTE) polypeptide construct and an isolated population of T cells that are autologous to the subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides devices and methods for insufflating abdomens of subjects under direct visualization. Such devices and methods, in some implementations, include features for cleaning the devices, and certain implementations of the methods permit procedures wherein it is not necessary to use a typical obturator to place a cannula, resulting in safer procedures.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
THE BRIGHAM AND WOMEN'S HOSPITAL (USA)
Inventor
Goldman, Aaron J.
Gonzalez, Gabriel
Frank, Natasha Y.
Abstract
Compositions comprising a cannabinoid and other compounds, such as terpenes, and methods of using such compositions. The disclosed compositions can be useful in, for example, treating and preventing esophageal adenocarcinoma and related diseases such as esophageal dysplasia, esophageal metaplasia, Barrett's Esophagus, gastroesophageal reflux disorder (GERD), or conditions associated with acid-biliary reflux.
Aspects of the disclosure provide nucleic acids and compositions comprising gene regulatory elements (GREs) for specific expression in nociceptor cells. Other aspects of the disclosure relate to the use of vectors and compositions comprising the gene regulatory elements for treating or managing pain and other neurological diseases in a subject in need thereof.
Disclosed are systems and methods for dynamic occupational satiety stimulation. The system includes a device that includes at least one outer arm, a motor, and a controller that operates the motor to actuate the at least one outer arm. The controller operates the motor to pre-prandially extend the at least one outer arm away from a body of the device, and the controller further operates the motor to post-prandially contract the at least one outer arm.
Described herein are compositions comprising NEDDtide peptides and methods of use thereof, e.g., to treat diseases associated with focal adhesion kinase (FAK) and Neural Precursor Cell Expressed, Developmentally Down-Regulated 9 (NEDD9) protein-protein interactions; such diseases include pulmonary arterial hypertension, other pulmonary vascular diseases, and solid tumor cancers, e.g., by inhibiting focal adhesion assembly.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical research; Medical and scientific research information in the fields of health care and blood disorders; Scientific research in the field of blood disorders; Scientific research; Medical and scientific research, namely, conducting clinical trials for others; Medical research in the field of blood disorders; Research and development in the fields of medicine and blood disorders Providing health information; Health care in the field of blood disorders; Hospital services; Physical rehabilitation; Consulting services in the field of medical care and blood disorders; Medical services; Medical services in the field of blood disorders; Health care
The present disclosure provides methods of suppressing the activation of microglial cells, methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of ameliorating or treating specific diseases that affect the CNS by nasally administering an anti-CD3 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical and scientific research information in the fields of health care and blood disorders; Medical and scientific research, namely, conducting clinical trials for others; Scientific research; Scientific research in the field of blood disorders; Research and development in the fields of medicine and blood disorders; Medical research in the field of blood disorders; Medical research Health care in the field of blood disorders; Physical rehabilitation; Medical services; Medical services in the field of blood disorders; Providing health information; Health care; Hospital services; Consulting services in the field of medical care and blood disorders
78.
miRNA REPROGRAMMING OF SMOOTH MUSCLE CELLS INTO ENDOTHELIAL CELLS
Described herein is a panel of three or four miRNAs that can be used to transdifferentiate vascular smooth muscle cells or fibroblasts into endothelial cells. As demonstrated herein, miR-143-3p and/or miR-145-5p inhibitors coupled with miR-5 146a-5p and miR-18lb-5p mimics were sufficient for accomplishing this transformation. This transdifferentiation protocol can be used to generate inducible endothelial cells that are transcriptionally, phenotypically, and functionally similar to other endothelial cells. This miRNA-engineered approach is useful in a range of cardiovascular-based therapies. In some embodiments, the methods use a 4-miRNA consisting of miR-143-3p and/or miR-145-Sp inhibitors, and miR-146a-5p and miR-181b-5p mimics, to produce iECs from SMCs or fibroblasts. In some embodiments, the SMC are isolated from aorta, coronary artery, pulmonary artery, umbilical artery, bladder smooth muscle cells, or derived from adipose tissue smooth muscle cells or progenitors, or blood derived circulating smooth muscle cell progenitors.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A uterine manipulator can include a shaft including a first end, a second end, and a channel along an axis of the shaft, a handle coupled to the first end of the shaft, and a triangular balloon coupled to the second end of the shaft. The triangular balloon can be configured to inflate upon insertion into a vagina via a fluid injected into the channel of the shaft.
A61B 17/42 - Gynaecological or obstetrical instruments or methods
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 17/29 - Forceps for use in minimally invasive surgery
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure
A61M 29/02 - Inflatable dilatorsDilators made of swellable materials
80.
COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCER
Aspects of the invention are drawn to compositions and methods for modulating CD8 Treg mobilization in the treatment of autoimmune disorders, rejection of transplanted organs and cancer.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
81.
RADIATION SOURCE AND BEAM LOCALIZATION USING MICROSTRUCTURED CONDUCTIVE ELEMENTS WITH SPATIOTEMPORAL DESIGN
Described here are systems and methods for determining the spatial location of a radiation source, such as a radiation source moving in a brachytherapy applicator (e.g., an afterloader catheter, a needle) during a brachytherapy procedure. Conductive elements coupled to the brachytherapy applicator are operable as radiation detectors that can measure spatiotemporal signal data to localize the position of the radiation source as it moves within the brachytherapy applicator. The conductive elements may include micro-structured wires (e.g., coaxial micro-structured wires), micro-structured conductive strips, conductive thin films, or other patterns of conductors. Other detector types may include ion chambers, solid-state detectors, or resistive electrodes.
Provided is an aryl hydrocarbon receptor (AHR) agonist, wherein the AHR agonist negatively regulates T cell differentiation as well as methods of using such AHR agonist. Also provided herein are methods of use of transcription factors and gene knockout to negatively regulate T cell differentiation.
In some aspects, the present disclosure provides a catheter system for use with radiation therapy. The catheter can include a core that is formed from a radioprotective material. The core may extend from a proximal end to a distal end along a longitudinal axis. The catheter system further includes a sleeve formed from a biocompatible material that extends about the core along the longitudinal axis. The sleeve may have an outer wall that is configured to extend through a biological lumen of a patient. The sleeve and the core are configured to cooperate to reduce a radiation dose received by tissue or organs in the patient that are proximate to the catheter system. The core may absorb or scatter radiation incident upon the radioprotective material, and the sleeve may absorb at least some of the radiation scattered by the core.
Provided herein are methods that use a combination of adeno-associated viruses (e.g., AAV.CPP.16 and AAV.CPP.21) and focused ultrasound for overcoming the blood-brain barrier, to deliver gene therapy reagents to the mammalian, e.g., human, brain.
Systems and methods are provided for digital witnessing of cellular structures. A system includes a processor and a non-transitory computer readable medium that stores instructions executable by the processor to provide an image interface configured to receive a first image and a similarity network. The similarity network compares the first image to a second image to determine a probability that the first and second images represent a same cellular structure or line of cellular structures. The similarity network is trained on a training set of samples, each including two images and a binary label. The training set includes positive examples, using two images of a same cellular structure or line of cellular structures, and negative examples, which use two images that are not of the same structure or line of cellular structures. An output device receives the probability or a categorical parameter representing the probability from the similarity network.
A nanoparticle composition including: a first polymer conjugated to a drug by a linker to form a first polymer compound, the first polymer compound having a net negative charge; and a second polymer conjugated to at least one positively charged group to form a second polymer compound, the second polymer compound having a net positive charge, and the first polymer compound and the second polymer compound interacting electrostatically to form a nanoparticle.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
87.
METABOLICALLY ENHANCED VD1 T CELLS AND USES THEREOF
Described herein are Vδ1 T cells that are cytotoxic in nature and exhibit improved metabolic activity. Also described here are methods for expansion of such Vδ1 T cells. Further provided are use of such Vδ1 T cells in methods of treatment.
Techniques are described for computer-implemented techniques for managing various aspects of the cardiac care pathway using machine learning. According to an embodiment, a method can include training an outcomes forecasting model to predict patient outcomes resulting from undergoing a cardiac valve procedure using multi-modal training data for a plurality of different patients, wherein the training comprising separately training different machine learning sub-models of the forecasting model to predict preliminary patient outcome data and mapping the preliminary patient outcome data to the patient outcomes, resulting in a trained version of the outcome forecasting model. The method further includes applying the trained version of the outcomes forecasting model to new multi-modal data for a new patient to predict the patient outcomes for the new patient resulting from undergoing the cardiac value procedure.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
89.
LONG-TERM STABILIZATION, FORMULATION AND TABLETING OF LIVE MICROBIAL CELLS
Escherichia coli (E. coli) Saccharomyces boulardii (S. boulardii), Lactobacillus plantarum (L. plantarum)Ensifer meliloti (E. meliloti)E. coli, S. boulardii, L. plantarum,E. melilotiE. meliloti to a subject in need thereof, methods of inducing bacterial growth in a subject or in a cell, tissue, or biological sample, and methods of inhibiting an enteric pathogen in a subject or in a cell, tissue, or biological sample. Further provided herein are methods of treating dysbiosis in a subject in need thereof.
In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A method of predicting a lifetime risk of having one or more cancer, in a subject suspected of having a BRCA l or BRCA2 mutation, including: obtaining a sample collected from the subject; determining the amounts of a circulating microRNA selected from the group consisting of: hsa-miR-20b-5p (SEQ ID NO: 4), hsa-miR-19b-3p (SEQ ID NO: 3), hsa-let-7b-5p (SEQ ID NO: 1), hsa-miR-320b (SEQ ID NO: 8), hsa-miR-139-3p (SEQ ID NO: 6), hsa-miR- 30d-5p, (SEQ ID NO 5), hsa-miR-17-5p (SEQ ID NO: 2), hsa-miR-182-5p (SEQ ID NO: 7), hsa-miR-421 (SEQ ID NO: 9), hsa-miR-375-3p (SEQ ID NO: 10); hsa-miRNA-106b-5p (SEQ ID NO: 11); hsa-miRNA-134-5p (SEQ ID NO: 12), hsa-miRNA-493-5p (SEQ ID NO: 13), hsa- miRNA-500a-3p (SEQ ID NO: 14), hsa-miR-1273h-3p (SEQ ID NO: 15), hsa-miR-4433a-3p (SEQ ID NO: 16), hsa-miR-4433b-5p (SEQ ID NO: 17), hsa-miR-485-3p (SEQ ID NO: 18), and has-miR-1304-3p (SEQ ID NO: 19); comparing the amounts of circulating microRNA as determined in step (b) to a statistical model; and identifying the presence of at least one mutation in the BRCA1 or BRCA2 gene.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
92.
Small Molecule Inhibitors of Formation of Neutrophil-Derived Extracellular Traps (NETosis) and Uses Thereof
Described herein are compositions and methods that inhibit class I and IIb HIDACs for use in inhibiting NETosis and conditions associated with NETosis.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
93.
TISSUE CATALYZED GROWTH OF POLYMER AS EPITHELIAL LININGS FOR THERAPY
The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials
A61L 24/06 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
The subject matter disclosed herein is generally directed to methods of treating autoimmune and inflammatory diseases characterized by a pathogenic immune cell state. Disclosed are novel gene dependencies in the pathogenic immune cell state. Also, disclosed are methods for modifying immune cells characterized by the pathogenic immune cell state.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
The invention relates, in part, to the use of compositions of poly N-acetylated glucosamine (PNAG) and antibodies specific to PNAG in the prevention and treatment of infections by certain PNAG-positive pathogens and in detection (including diagnostic) methods.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K 16/14 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from fungi, algae or lichens
C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
96.
System and method for protein corona sensor array for early detection of diseases
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Described herein are methods for making and using antibodies that bind specifically to soluble oligomers of amyloid beta protein (oAβ), and methods of use thereof in diagnosis and treatment of diseases related to formation of pathogenic oligomers of oAβ. Also provided are T helper cell (Th) carrier peptides that can be conjugated to peptide immunogens to stimulate targeted humoral immune responses to the desired antigen.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
98.
SYSTEM AND METHOD FOR CELL LEVITATION AND MONITORING
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
BETH ISRAEL DEACONESS MEDICAL CENTER (USA)
Inventor
Demirci, Utkan
Ghiran, Ionita
Tasoglu, Savas
Davis, Ronald W.
Steinmetz, Lars
Durmus, Naside Gozde
Tekin, Huseyin Cumhur
Abstract
Magnetic cell levitation and cell monitoring systems and methods are disclosed. A method for separating a heterogeneous population of cells is performed by placing a microcapillary channel containing the heterogeneous population of cells in a magnetically-responsive medium in the disclosed levitation system and separating the cells by balancing magnetic and corrected gravitational forces on the individual cells. A levitation system is also disclosed, having a microscope on which the microcapillary channel is placed and a set of two magnets between which the microcapillary channel is placed. Additionally, a method for monitoring cellular processes in real-time using the levitation system is disclosed.
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
B03C 1/32 - Magnetic separation acting on the medium containing the substance being separated, e.g. magneto-gravimetric-, magnetohydrostatic-, or magnetohydrodynamic separation
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
C12Q 1/18 - Testing for antimicrobial activity of a material
G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
G01N 15/06 - Investigating concentration of particle suspensions
G01N 15/1031 - Investigating individual particles by measuring electrical or magnetic effects
G01N 27/76 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids by investigating susceptibility
G01N 33/487 - Physical analysis of biological material of liquid biological material
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
99.
COMPOSITIONS AND METHODS FOR TREATING A SEIZURE DISORDER IN A SELECTED SUBJECT
The disclosure provides compositions and methods for characterizing or treating a seizure disorder (e.g., focal epilepsy, temporal lobe epilepsy, mesial temporal lobe epilepsy, and related disorders).
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Disclosed are compositions and methods of promoting transplantation tolerance, treating an immune disorder associated with graft transplantation, and promoting organ survival in an organ transplanted into a subject. The methods include administering anti-CD74 antibodies or CD74-deficient Treg cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
